| Fetroja (cefiderocol) / Shionogi |
NCT03862040: Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia |
|
|
| Terminated | 1 | 7 | US | Cefiderocol, S-649266), Standard of Care Antibiotic | Shionogi | Bacterial Pneumonia | 10/19 | 10/19 | | |
NCT05395104: A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants |
|
|
| Completed | 1 | 14 | US | Midazolam, Cefiderocol | Shionogi | Healthy Volunteers | 07/22 | 07/22 | | |
ChiCTR2300076607: A phase 1, open-label, single-center, single and multiple intravenous infusion dose study of Cefiderocol in Chinese healthy adult subjects |
|
|
| Completed | 1 | 12 | | Cefiderocol for Injection | Huashan Hospital, Fudan University; Ping An-Shionogi Co., Ltd., Supported by Ping An-Shionogi Co., Ltd. | Complicated urinary tract infections, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, and treatment of infections caused by aerobic gram-negative bacteria | | | | |
NCT05373615: Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy |
|
|
| Active, not recruiting | 1 | 16 | US | Cefiderocol | Hartford Hospital, Shionogi Inc. | Pharmacokinetics | 10/24 | 10/24 | | |
| Recruiting | 1 | 8 | US | Cefiderocol, Fetroja | Joseph L. Kuti, PharmD, Shionogi Inc. | Sepsis | 07/24 | 07/24 | | |
NCT06547554: A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants |
|
|
| Recruiting | 1 | 40 | US | Xeruborbactam, QPX7728, Cefiderocol, Xeruborbactam/Cefiderocol, Dextrose 5% in water | Qpex Biopharma, Inc., Shionogi Inc., Biomedical Advanced Research and Development Authority | Bacterial Infections | 12/25 | 12/25 | | |
